Posts

Pfizer Inc. on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment in 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories.

Drugmakers including Pfizer Inc., GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC, and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.

Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.

The pharmaceutical giant, still riding high on the sales of Comirnaty and Paxlovid, is looking to a future of innovative oncology drugs and vaccines based on mRNA technology.